Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

PHASE2

Phase

TERMINATED

Status

Enrollment

NIH

Sponsor class

Stopped Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first line treatment for Mesothelioma, the principal investigator decided to end the study early (prior to reaching enrollment goal).

Conditions

Mesothelioma

Interventions

DRUG: LMB-100
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)